National Academies Press: OpenBook
« Previous: 9 Looking to the Future
Suggested Citation:"References." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

References

Alving, B. 2007. Academic health center consortium to enhance drug monitoring. http://www.iom.edu/Object.File/Master/41/335/Alving%20slides.pdf (accessed July 17, 2007).

Breckenridge Institute. 2006. Independent verification and validation of AERS II requirements process. Breckenridge, CO: Breckenridge Institute.

Coalition for a Stronger FDA. 2007. Just the facts. http://www.fdacoalition.org/facts.php (accessed May 29, 2007).

DiMasi, J. A., and H. G. Grabowski. 2007. The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics 28(4–5):469–479.

Federal Register. 2007. Report on the performance of drug and biologics firms in conducting postmarketing commitment studies; availability. http://a257.g.akamaitech.net/7/257/2422/01jan20071800/edocket.access.gpo.gov/2007/pdf/E7-1749.pdf (accessed May 31, 2007).

FDA (Food and Drug Administration). 2004. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (accessed July 11, 2007).

FDA. 2007a. FDA’s mission statement. http://www.fda.gov/opacom/morechoices/mission.html (accessed May 31, 2007).

FDA. 2007b. The future of drug safety—promoting and protecting the health of the public: FDA’s response to the Institute of Medicine’s 2006 report. http://www.fda.gov/oc/reports/iom013007.pdf (accessed May 9, 2007).

Galson, S. 2007. The FDA response to the IOM Drug Safety Report, March 12, 2007, Washington, DC. http://www.iom.edu/Object.File/Master/41/347/Galson%20slides.pdf (accessed July 17, 2007).

Gilbert, J., P. Henske, and A. Singh. 2003. Rebuilding big pharma’s business model. http://www.bain.com/bainweb/PDFs/cms/Marketing/rebuilding_big_pharma.pdf (accessed August, 8, 2007).

IOM (Institute of Medicine). 2007a. The future of drug safety: Promoting and protecting the health of the public. Washington, DC: The National Academies Press.

IOM. 2007b. Preventing medication errors. Washington, DC: The National Academies Press.

Suggested Citation:"References." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

Li, J. S., E. L. Eisenstein, H. G. Grabowski, E. D. Reid, B. Mangum, K. A. Schulman, J. V. Goldsmith, M. D. Murphy, R. M. Califf, and D. K. Benjamin Jr. 2007. Economic return of clinical trials performed under the pediatric exclusivity program. Journal of the American Medical Association 297(5):480–488.

Lloyd, I. 2002–2003. New technologies, products in development, and attrition rates: R&D revolution still around the corner. PAREXEL’s pharmaceutical R&D statistical sourcebook. Waltham, MA: PAREXEL International Corporation.

Owens, J. 2007. 2006 drug approvals: Finding the niche. Nature Reviews Drug Discovery 6:99–100.

Platt, R. 2007. Using health plan data to improve post-marketing safety. http://www.iom.edu/Object.File/Master/41/443/Platt%20slides.pdf (accessed July 17, 2007).

Walker, A. 2007. Routine healthcare surveillance is here. http://www.iom.edu/Object.File/Master/41/375/Walker%20slides.pdf (accessed July 17, 2007).

Wilensky, G. R. 2006. Developing a center for comparative effectiveness information. Health Affairs 25(6):w572–w585.

Young, R. C., C. R. Aldige, D. Balma, J. G. Bartlett, E. J. Benz, W. P. Bro, M. A. Caligiuri, B. A. Chabner, W. S. Dalton, N. Davenport-Ennis, M. A. Friedman, W. N. Hait, G. D. Hammond, P. J. Limburg, S. Lippman, H. K. Lyerly, J. L. Marshall, K. H. Mooney, J. M. Olefsky, R. L. Schilsky, E. V. Sigal, and J. W. Yates. 2007. Drug safety and drug efficacy: Two sides of the same coin (A White Paper Report). http://www.focr.org/drugsafetyreport/drugsafetyreport.pdf (accessed May 9, 2007).

Zarin, D. 2007. Resource implications of IOM recommendations for trial registration and results database. http://www.iom.edu/Object.File/Master/41/379/Zarin%20slides.pdf (accessed July 17, 2007).

Suggested Citation:"References." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

This page intentionally left blank.

Suggested Citation:"References." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 78
Suggested Citation:"References." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 79
Suggested Citation:"References." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 80
Next: Appendix A Workshop Agenda »
Challenges for the FDA: The Future of Drug Safety: Workshop Summary Get This Book
×
Buy Paperback | $44.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

As the principal agency regulating food, drugs, medical devices, and biological products used by Americans, the U.S. Food and Drug Administration (FDA) serves one of the most critical consumer protection functions of the federal government. The FDA's reach is enormous, regulating products that represent roughly 25 percent of all consumer spending in the United States. Since 1992, however, federal funding for the agency has diminished, and the FDA's Center for Drug Evaluation and Research (CDER) currently relies on the fees it receives from the industry it regulates to fund the majority of its drug regulation functions. Prescription drug safety is receiving heightened press coverage and congressional scrutiny as a result of recent, highly publicized events, such as the recall of Vioxx because of its link to heart attacks, and the link between certain antidepressants (selective serotonin reuptake inhibitors, or SSRIs) and an increased risk of suicidal ideation in children.

To address these concerns, the FDA in 2005 commissioned the Institute of Medicine (IOM) to conduct an independent assessment of the current U.S. drug safety system. In September 2006, the IOM committee released its report—The Future of Drug Safety: Promoting and Protecting the Health of the Public—which included 25 recommendations for improving the system for drug safety review. The committee identified four major vulnerabilities in the U.S. drug safety system: (1) chronic underfunding; (2) organization problems, particularly inadequate integration of pre-and postmarket data review; (3) a range of technical problems related to the insufficient quantity and quality of postmarket data and inadequate capability to systematically monitor the risks and benefits of drugs after marketing; and (4) unclear regulatory authority and insufficiently flexible regulatory tools. Since the IOM report was issued, the FDA has taken a number of steps toward implementing the recommended improvements. Like many government agencies, however, the FDA is financially strained by its existing responsibilities, and fully implementing the recommended improvements to the drug safety system would require significant financial commitments.The IOM report addressed some of the costs associated with its recommendations, but left many unanswered questions about the resources required to fully achieve the envisioned improvements. To better understand the types and magnitude of resources required to achieve the goals of the IOM report, the IOM's Forum on Drug Discovery, Development, and Translation convened a 1-day symposium in March 2007.
Challenges for the FDA: The Future of Drug Safety, Workshop Summary explains the presentations and discussions in seven key areas: addressing the FDA's resource challenges; strengthening the scientific base of the agency; integrating pre- and postmarket review; enhancing postmarket safety monitoring; conducting confirmatory drug safety and efficacy studies; enhancing the value of clinical trial registration; and enhancing the FDA's postmarket regulation and enforcement.
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!